Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene reported a Q2 net loss of $34.5 million, driven by higher R&D and G&A costs, but secured its financial position through an oversubscribed $144 million public offering that extends cash runway into the first quarter of 2029. Interim Phase 1/2 data for NGN-401 demonstrated that 100% of participants improved on CGI-I score and gained an average of 4.7 developmental milestones, with continued improvement observed through 30 months and no plateau in efficacy.
Key figures
- Runway
- Q1 2029
- Net loss
- 34500000
- Ga expenses
- 11200000
- Rd expenses
- 25500000
- Cash pro forma
- 360200000
- Offering proceeds gross
- 144000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.